Establishing the Bioequivalence Safe Space for Immediate-Release Oral Dosage Forms using Physiologically Based Biopharmaceutics Modeling (PBBM): Case Studies-Reference-Cited by-同舟云学术

Establishing the Bioequivalence Safe Space for Immediate-Release Oral Dosage Forms using Physiologically Based Biopharmaceutics Modeling (PBBM): Case Studies

Published:2021-12 Issue:12 Volume:110 Page:3896-3906
ISSN:0022-3549
Container-title:Journal of Pharmaceutical Sciences
language:en
Short-container-title:Journal of Pharmaceutical Sciences

Author:

Heimbach Tycho,Kesisoglou Filippos,Novakovic Jasmina,Tistaert Christophe,Mueller-Zsigmondy Martin^ORCID,Kollipara Sivacharan^ORCID,Ahmed Tausif,Mitra Amitava,Suarez-Sharp Sandra

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference30 articles.

1. The Use of Physiologically Based Pharmacokinetic Analyses — Biopharmaceutics Applications for Oral Drug Product Development, Manufacturing Changes, and Controls Guidance for Industry,2020

2. Applications of clinically relevant dissolution testing: workshop summary report;Suarez-Sharp;AAPS J,2018

3. Regulatory experience with In Vivo In Vitro Correlations (IVIVC) in new drug applications;Suarez-Sharp;AAPS J,2016

4. Translational modeling strategies for orally administered drug products: academic, industrial and regulatory perspectives;Suarez-Sharp;Pharm Res,2020

5. Dissolution and translational modeling strategies toward establishing an in vitro-in vivo link-a workshop summary report;Heimbach;AAPS J,2019

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Physiologically based in vitro – in vivo correlation of modified release oral formulations with non-linear intestinal absorption: A case study using mirabegron;European Journal of Pharmaceutics and Biopharmaceutics;2024-11

2. A Semi-Mechanistic Physiologically Based Biopharmaceutics Model to Describe Complex and Saturable Absorption of Metformin: Justification of Dissolution Specifications for Extended Release Formulation;AAPS PharmSciTech;2024-08-21

3. Biopredictive Dissolutions for Conventional Oral IR, MR and Non-Oral Formulations – Current Status and Future Opportunities;Journal of Drug Delivery Science and Technology;2024-08

4. Physiologically Based Biopharmaceutics Modeling for Gefapixant IR Formulation Development and Defining the Bioequivalence Dissolution Safe Space;The AAPS Journal;2024-06-11

5. Enhanced Bioavailability and Reduced Variability of Dasatinib and Sorafenib with a Novel Amorphous Solid Dispersion Technology Platform;Clinical Pharmacology in Drug Development;2024-05-29